Attitudes of clinicians following large-scale pharmacogenomics implementation.
Clinician attitudes toward multiplexed genomic testing may be vital to the success of translational programs. We surveyed clinicians at an academic medical center about their views on a large pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced Decisions in Care and Treatment) program. Participants were asked about test ordering, major factors influencing use of results, expectations of efficacy and responsibility for applying results to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence patients' response to drug therapy. The majority (92%) favored immediate, active notification when a clinically significant drug-genome interaction was present. However, clinicians were divided on which providers were responsible for acting on a result when a prescription change was indicated and whether patients should be directly notified of a significant result. We concluded genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to appropriately assign clinical responsibility for actionable results from a multiplexed panel.The Pharmacogenomics Journal advance online publication, 11 August 2015; doi:10.1038/tpj.2015.57.
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J F
JF
Peterson
Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.
J R
JR
Field
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Y
Y
Shi
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Anesthesiology, Vanderbilt University Medical Center, Nashville, TN, USA.
J S
JS
Schildcrout
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J C
JC
Denny
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
T L
TL
McGregor
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.
S L
SL
Van Driest
Vanderbilt Institute for Clinical and Translational Research, Nashville, TN, USA.
J M
JM
Pulley
Centers for Disease Control and Prevention, Atlanta, GA, USA.
I M
IM
Lubin
University of Texas Medical Branch, Galveston, TX, USA.
M
M
Laposata
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN, USA.
D M
DM
Roden
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.|Center for Biomedical Ethics and Society, Vanderbilt University Medical Center, Nashville, TN, USA.
E W
EW
Clayton
D000328:Adult; D000368:Aged; D001291:Attitude of Health Personnel; D064420:Drug-Related Side Effects and Adverse Reactions / Q000235:genetics*; D005260:Female; D005838:Genotype; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D008297:Male; D008875:Middle Aged; D010465:Perception; D010597:Pharmacogenetics; D000071185:Pharmacogenomic Testing; D000071184:Pharmacogenomic Variants / Q000235:genetics*; D010641:Phenotype; D010820:Physicians / Q000523:psychology*; D057285:Precision Medicine; D011237:Predictive Value of Tests; D018570:Risk Assessment; D012307:Risk Factors; D011795:Surveys and Questionnaires; D055815:Young Adult